Two oncogenic events linked to poor T cell infiltration and primary immunotherapy resistance are tumor cell-intrinsic β-catenin pathway activation and also PTEN loss-of-function mutation or deletion [16, 18]. The gene discussed is PTEN; the disease is neoplasm.